Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

A crowded field could take years to thin out.

Could CRISPR Therapeutics Stock Help You Retire a Millionaire?

CRISPR Therapeutics' clinical programs are progressing nicely, showing excellent safety and efficacy, validating the prospects of its novel technology as a disruptive force in the biotech industry. Directionally, we see CRSP focusing on next-generation CAR-T and regenerative therapies for diseases with robust prevalence, increasing the chances of commercial success.

Crispr Therapeutics: Lucrative Partnerships And Promising Data Increase Its Appeal

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to Watch

Editas Medicine

Intellia Therapeutics

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. The post Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today appeared first on InvestorPlace.

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 40% to its current level of around $119.

What's Next For CRISPR Stock After An 11% Fall In A Week?

Looking for a terrific value in the biotechnology space? It doesn't get much better than CRSP stock, which just entered a buy zone.

Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics

ARK Genomic Revolution Multi-Sector ETF

Beam Therapeutics

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

How Are Genomics ETFs Responding to Q2 Earnings?

The stock dropped roughly $40 per share over the course of the month.

Why CRISPR Therapeutics Stock Fell 25.2% in July

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today appeared first on InvestorPlace.

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today

Vertex Pharmaceuticals

Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.

Better Buy: Vertex vs. CRISPR

Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate. The post CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today appeared first on InvestorPlace.

CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today

CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.

CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 125.30% and 32.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $119, marking a -0.63% move from the previous day.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

- More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

CRSP stock may end up being a pioneer, or it may fizzle. The timeline until we know is typical of biotech stocks.

Crispr Therapeutics Represents the Best of Emerging Biotechnology

It's already well on its way, but the road ahead will be long.

Is CRISPR Therapeutics a Millionaire-Maker Stock?

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning. The post Crispr Therapeutics Has Bullish DNA appeared first on InvestorPlace.

Crispr Therapeutics Has Bullish DNA

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) to Report Q2 Results: Wall Street Expects Earnings Growth

While the technologies that undergird CRSP stock is nothing short of mind-blowing, you should be aware of the ethical risks. The post Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?

Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?

CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week

Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.

The Top 3 Gene Editing Stocks to Own for the Next Decade

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a larger sell-off in the gene-editing companies drove the stock price down nearly 32% to its.

News for CRISPR Therapeutics Stock (CRSP)